Oruka Therapeutics, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-41.2M | $-31.8M | $-29.6M | $-30.3M | $-24.6M | $-21.0M | $-22.2M | $-2.0M |
| Depreciation & Amortization | — | — | — | — | — | — | $3.0K | $3.0K |
| Depreciation | $43.0K | $43.0K | $28.0K | $20.0K | $19.0K | $16.0K | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $7.3M | $7.0M | $4.1M | $10.2M | $5.1M | $4.9M | $112.0K | $114.0K |
| Net Cash from Operating Activities | $-33.1M | $-23.6M | $-22.6M | $-21.6M | $-23.1M | $-20.9M | $-2.6M | $-1.5M |
| Investing Activities | ||||||||
| Capital Expenditures | $0 | $73.0K | $63.0K | $99.0K | $34.0K | $13.0K | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-410.9M | $-14.4M | $-22.0M | $-122.4M | $4.9M | $42.9M | $0 | $0 |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $663.0M | $40.6M | — | — | — | — | $14.0K | $0 |
| Net Change in Cash | — | — | — | — | — | — | $-2.6M | $-1.5M |
| Free Cash Flow | $-33.1M | $-23.7M | $-22.7M | $-21.7M | $-23.2M | $-20.9M | — | — |